Avertix Medical has filed a notice of an exempt offering of securities to raise $5 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Avertix Medical is raising up to $5,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Avertix Medical
Avertix Medical is a pioneering medical device company founded in 2001 by Drs. Robert, Tim, and David Fischell, who are noted entrepreneurs and inventors in medical technologies. The company specializes in real-time, implantable heart attack detection technology, with its flagship product being the Guardian System. This FDA-approved Class III implantable device is designed to detect acute thrombotic coronary occlusion, including silent and atypical symptomatic heart attacks, and provides alerts to patients and healthcare professionals. Avertix holds a robust portfolio of over 50 issued U.S. patents related to detecting cardiac events and patient alerting, demonstrating its commitment to innovation in cardiovascular care. The Guardian System has also been recognized with a Transitional Pass-Through status by CMS, effective January 1, 2022, and the company is focused on improving long-term management and outcomes for high-risk coronary disease patients.
To learn more about Avertix Medical, visit https://avertix.com/
Avertix Medical Linkedin Page: https://www.linkedin.com/search/results/companies/?keywords=Avertix%20Medical
Contact:
Tim Moran, Chief Executive Officer
732-542-5551
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
